Insider Transactions in Q4 2024 at Alkermes Plc. (ALKS)
Insider Transaction List (Q4 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 09
2024
|
Cato T Laurencin Director |
SELL
Open market or private sale
|
Direct |
2,691
-10.47%
|
$83,421
$31.85 P/Share
|
|
Dec 09
2024
|
Cato T Laurencin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,691
+9.48%
|
$59,202
$22.52 P/Share
|
|
Dec 09
2024
|
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
61,151
-56.24%
|
$1,956,832
$32.07 P/Share
|
|
Dec 09
2024
|
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
48,997
+12.15%
|
$1,077,934
$22.7 P/Share
|
|
Dec 08
2024
|
Cato T Laurencin Director |
SELL
Payment of exercise price or tax liability
|
Direct |
958
-4.0%
|
$29,698
$31.46 P/Share
|
|
Dec 08
2024
|
Cato T Laurencin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,163
+14.8%
|
-
|
|
Dec 05
2024
|
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
9,221
-13.37%
|
$285,851
$31.5 P/Share
|
|
Dec 04
2024
|
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
14,349
-17.23%
|
$430,470
$30.77 P/Share
|
|
Nov 27
2024
|
Christian Todd Nichols SVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
5,208
-7.9%
|
$151,032
$29.15 P/Share
|
|
Nov 11
2024
|
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
58,996
-41.46%
|
$1,769,880
$30.08 P/Share
|
|
Nov 11
2024
|
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
43,058
+23.23%
|
$861,160
$20.03 P/Share
|
|
Nov 06
2024
|
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
10,471
-9.54%
|
$303,659
$29.53 P/Share
|